Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 6;10(19):4594.
doi: 10.3390/jcm10194594.

Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review

Affiliations
Review

Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review

Andrea Marino et al. J Clin Med. .

Abstract

Enterococcus faecalis infective endocarditis (EFIE) continues to represent a potentially fatal infectious disease characterized by elevated morbidity and mortality. Despite advances in antimicrobial therapy, changing demographics and the reduced availability of useful antibiotics combined with the dissemination of multi-drug resistant strains, the mortality rate remained unchanged in the last decades. Nowadays, optimizing the antibiotic regimen is still of paramount importance. Historically, aminoglycosides were considered as a cornerstone for treatment even though their use is associated with a high risk of kidney failure. It is against this background that, in recent years, several studies have been carried in order to assess the validity of alternative therapeutic approaches, including combinations of beta-lactams, that, acting synergistically, have yielded useful results in different clinical settings. In this scenario, we searched and critically report clinical studies assessing the efficacy and safety of double beta-lactam therapy in treating EFIE.

Keywords: Enterococcus faecalis; ampicillin plus ceftriaxone; antibiotic resistance; double beta-lactams therapy; infective endocarditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Dahl A., Bruun N.E. Enterococcus faecalis infective endocarditis: Focus on clinical aspects. Expert Rev. Cardiovasc. Ther. 2013;11:1247–1257. doi: 10.1586/14779072.2013.832482. - DOI - PubMed
    1. Fisher K., Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155:1749–1757. doi: 10.1099/mic.0.026385-0. - DOI - PubMed
    1. McDonald J., Olaison L., Anderson D., Hoen B., Miro J., Eykyn S., Abrutyn E., Fowler V., Habib G., Selton-Suty C., et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am. J. Med. 2005;118:759–766. doi: 10.1016/j.amjmed.2005.02.020. - DOI - PubMed
    1. Miro J.M., Pericas J.M., Del Rio A. A new era for treating enterococcus faecalis endocarditis ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: That is the question! Circulation. 2013;127:1763–1766. doi: 10.1161/CIRCULATIONAHA.113.002431. - DOI - PubMed
    1. Fernández-Hidalgo N., Escolà-Vergé L., Pericàs J.M. Enterococcus faecalis endocarditis: What’s next? Future Microbiol. 2020;15:349–364. doi: 10.2217/fmb-2019-0247. - DOI - PubMed

LinkOut - more resources